MARKET

GNPX

GNPX

Genprex Inc
NASDAQ
1.780
-0.080
-4.30%
After Hours: 1.800 +0.02 +1.12% 19:48 02/20 EST
OPEN
1.830
PREV CLOSE
1.860
HIGH
1.850
LOW
1.750
VOLUME
223.64K
TURNOVER
--
52 WEEK HIGH
55.00
52 WEEK LOW
1.710
MARKET CAP
4.13M
P/E (TTM)
-0.0337
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GNPX last week (0209-0213)?
Weekly Report · 6d ago
Genprex Gains Australian Patent Acceptance for REQORSA Therapy
TipRanks · 02/10 13:53
Genprex’s patent application for Reqorsa Gene Therapy accepted by IP Australia
TipRanks · 02/10 13:05
Genprex erhält Patenterteilungsankündigung für Reqorsa-Gentherapie-Kombination in Australien
Reuters · 02/10 13:02
Genprex Announces IP Australia's Acceptance of Patent Application for Reqorsa® Gene Therapy and PD-L1 Antibody Combination in Cancer Treatment
Reuters · 02/10 13:02
GENPREX ANNOUNCES IP AUSTRALIA'S INTENT TO GRANT PATENT FOR REQORSA® GENE THERAPY IN COMBINATION WITH PD-L1 ANTIBODIES TO TREAT CANCERS
Reuters · 02/10 13:00
Weekly Report: what happened at GNPX last week (0202-0206)?
Weekly Report · 02/09 10:14
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 02/06 21:05
More
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.

Webull offers Genprex Inc stock information, including NASDAQ: GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.